MCID: CRB039
MIFTS: 68

Cerebrovascular Disease

Categories: Cardiovascular diseases

Aliases & Classifications for Cerebrovascular Disease

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An artery disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to peripheral artery disease and vascular dementia, and has symptoms including sleeplessness, equilibration disorder and vertigo/dizziness. An important gene associated with Cerebrovascular Disease is NOTCH3 (Notch 3), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Selenium Micronutrient Network. The drugs Heparin and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 72 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 292)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 32.5 ACE APOB CRP SELP
2 vascular dementia 32.1 ACE ACHE APOE APP MTHFR NOTCH3
3 cerebral atherosclerosis 31.4 ACE APOA1 APOE MTHFR
4 dementia 31.1 ACHE APOE APP NOTCH3
5 sleep apnea 30.6 ACE APOE CRP REN
6 thrombosis 30.4 F2 MTHFR PLAT SELP
7 acute myocardial infarction 30.3 ACE CRP PLAT SELP
8 ischemic heart disease 30.3 ACE APOA1 APOB APOE CRP MTHFR
9 portal vein thrombosis 30.3 F2 MTHFR SELP
10 hemorrhage, intracerebral 30.3 ACE APOE APP COL4A1 PLAT
11 migraine with aura 30.3 ACE MTHFR NOTCH3
12 ischemia 30.3 ACE APP PLAT PON1 SELP
13 thrombophilia due to thrombin defect 30.2 F2 MTHFR PLAT
14 aortic aneurysm, familial abdominal, 1 30.2 ACE APOE CRP
15 homocysteinemia 30.2 CBS CRP F2 MTHFR MTR
16 patent foramen ovale 30.2 F2 MTHFR PLAT
17 carotid artery disease 30.2 ACE APOA1 APOB APOE CRP
18 sudden sensorineural hearing loss 30.2 F2 MTHFR
19 body mass index quantitative trait locus 11 30.1 APOA1 APOB APOE CRP PON1
20 carotid stenosis 30.1 ACE APOE CRP MTHFR SELP
21 atrial fibrillation 30.1 ACE AGTR1 F2 PLAT SELP
22 thrombophilia 30.1 CBS F2 MTHFR PLAT
23 coronary heart disease 1 30.0 ACE APOA1 APOB APOE CRP CX3CR1
24 stroke, ischemic 30.0 ACE AGTR1 APOB APOE CRP F2
25 dementia, lewy body 29.9 ACHE APOE APP
26 kidney disease 29.8 ACE AGTR1 APOE REN
27 congestive heart failure 29.5 ACE ADM AGTR1 REN
28 heart disease 29.4 ACE ADM AGTR1 APOB APOE CRP
29 coronary artery anomaly 29.4 ACE AGTR1 APOA1 APOB APOE CRP
30 pulmonary hypertension 29.3 ACE ADM PLAT REN
31 arteries, anomalies of 29.3 ACE AGTR1 APOA1 APOB APOE CRP
32 vascular disease 28.8 ACE APOA1 APOB APOE CBS CRP
33 myocardial infarction 28.3 ACE ADM AGTR1 APOA1 APOB APOE
34 basal ganglia cerebrovascular disease 12.0
35 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 11.6
36 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.3
37 fabry disease 11.1
38 sneddon syndrome 10.9
39 pituitary adenoma 1, multiple types 10.8
40 pituitary adenoma 4, acth-secreting 10.8
41 peripheral arterial occlusive disease 1 10.8
42 multisystemic smooth muscle dysfunction syndrome 10.8
43 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.8
44 moderate and severe traumatic brain injury 10.8 ACE APOE
45 intracranial aneurysm 10.8
46 malignant otitis externa 10.7 CRP F2
47 senile plaque formation 10.7 APOE APP
48 porencephaly 10.7 COL4A1 F2 MTHFR
49 hepatoportal sclerosis 10.7 ACE F2
50 ischemic neuropathy 10.7 CRP F2 MTHFR

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 40)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


sleeplessness, equilibration disorder, vertigo/dizziness, chronic pain, tremor, syncope, seizures, sciatica, pain, headache, edema, chest pain, back pain, angina pectoris, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 PLAT ADM MTHFR APOE ACE MTR
2 cardiovascular system MP:0005385 10.44 APOB PLAT ADM APOE ACE AGTR1
3 behavior/neurological MP:0005386 10.36 F2 PLAT ADM ACE AGTR1 NOTCH3
4 growth/size/body region MP:0005378 10.36 F2 APOB PLAT MTHFR ACE AGTR1
5 hematopoietic system MP:0005397 10.31 F2 PLAT ADM ACE AGTR1 NOTCH3
6 mortality/aging MP:0010768 10.31 APOB PLAT ADM MTHFR MTR ACE
7 immune system MP:0005387 10.3 APOB PLAT ADM ACE AGTR1 NOTCH3
8 cellular MP:0005384 10.26 NOTCH3 APOB ADM PLAT PON1 APOA1
9 integument MP:0010771 10.13 F2 MTHFR PLAT ADM APOA1 NOTCH3
10 nervous system MP:0003631 10.13 F2 APOB MTHFR PLAT AGTR1 NOTCH3
11 muscle MP:0005369 10.07 APOB PLAT ADM NOTCH3 ACHE APP
12 reproductive system MP:0005389 9.97 APOB PLAT ADM MTHFR ACE NOTCH3
13 renal/urinary system MP:0005367 9.91 ADM ACE AGTR1 NOTCH3 REN CX3CR1
14 respiratory system MP:0005388 9.56 ACHE F2 ADM PLAT NOTCH3 SELP
15 vision/eye MP:0005391 9.28 ACHE APOB MTHFR PLAT NOTCH3 CX3CR1

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 850)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3 9005-49-6 46507594 772
2
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 51-41-2 439260
3
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-02-2 5743
5
Nicotine Approved Phase 4 54-11-5 89594 942
6
Glyburide Approved Phase 4,Phase 3,Phase 2,Phase 1 10238-21-8 3488
7
Probucol Approved, Investigational Phase 4 23288-49-5 4912
8
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
9
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
10
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 7440-66-6 32051 23994
11
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
12
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
13
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2 50-18-0, 6055-19-2 2907
14
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3 59467-70-8 4192
15
Nicardipine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 55985-32-5 4474
16
Dipyridamole Approved Phase 4,Phase 3,Phase 2 58-32-2 3108
17
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
18
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
19
Pantoprazole Approved Phase 4,Phase 2 102625-70-7 4679
20
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
21
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Early Phase 1 103-90-2 1983
22
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
23
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
24
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
25
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2 58-93-5 3639
26
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
27
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
28
Atenolol Approved Phase 4,Phase 3 29122-68-7 2249
29
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 120202-66-6, 113665-84-2 60606
30
Nitroglycerin Approved, Investigational Phase 4,Phase 3,Phase 2 55-63-0 4510
31
Warfarin Approved Phase 4,Phase 2,Phase 3,Phase 1 81-81-2 54678486 6691
32
Donepezil Approved Phase 4,Phase 3,Phase 1,Phase 2 120014-06-4 3152
33
Galantamine Approved Phase 4,Phase 3,Phase 2,Phase 1 357-70-0 9651
34
Rivastigmine Approved, Investigational Phase 4,Phase 3 123441-03-2 77991
35
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-84-3 187
36 Piracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 7491-74-9
37
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
38
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
39
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2 73963-72-1 2754
40
Histamine Approved, Investigational Phase 4,Phase 2,Early Phase 1 51-45-6, 75614-87-8 774
41
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55142-85-3 5472
42
Nimodipine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 66085-59-4 4497
43
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
44
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
45
Amiloride Approved Phase 4 2609-46-3, 2016-88-8 16231
46
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
47
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
48
Antipyrine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 60-80-0 2206
49
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 50-24-8 5755
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 2 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 4335)

# Name Status NCT ID Phase Drugs
1 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD Unknown status NCT02444637 Phase 4 Rivastigmine
2 Nimodipine for Treating Acute Massive Cerebral Infarction Unknown status NCT02248233 Phase 4 Nimodipine;Saline + citicoline
3 Effects of Angiotensin II Receptor Blocker Compared With Diuretics in High-risk Hypertensive Patients Unknown status NCT01011660 Phase 4 Amlodipine, Telmisartan, Amiloride Compound , Simvastatin
4 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
5 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
6 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
7 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4 Cilostazol;Aspirin
8 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
9 Rajavithi Health Promotion Project (Population Base Cohort) Unknown status NCT00368095 Phase 4
10 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
11 The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients Unknown status NCT02361307 Phase 4
12 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
13 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
14 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
15 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
16 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
17 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
18 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
19 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
20 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
21 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
22 Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
23 Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban Unknown status NCT02549963 Phase 4 Rivaroxaban
24 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
25 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
26 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
27 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
28 Safety Study of Melatonin in Stroke Patients Unknown status NCT01863277 Phase 4 Melatonin;placebo
29 Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
30 Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
31 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
32 PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
33 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
34 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
35 Valsartan Efficacy on Modest Blood Pressure Reduction in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
36 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
37 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
38 Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting Unknown status NCT01572623 Phase 4 Clopidogrel;Atorvastatin
39 Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis Unknown status NCT02224209 Phase 4
40 PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
41 Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy Unknown status NCT01918722 Phase 4 ICH-1(herbal medicine with Hirudo, Tabanus);placebo;ICH-2(herbal medicine without Hirudo, Tabanus)
42 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
43 The Preventive Effect of Escitalopram on Depression and Related Emotional Disorders in Acute Stroke Patients Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
44 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
45 Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
46 The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Unknown status NCT01042574 Phase 4 Clevidipine butyrate
47 Treatment of Cranial Internal Carotid Artery Aneurysm With Willis Covered Stent and Coil Embolization Unknown status NCT01029938 Phase 4
48 HYdrogel Coil Versus Bare Platinum Coil in Recanalization Imaging Data Study Unknown status NCT01516658 Phase 4
49 The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels Unknown status NCT01926834 Phase 4 Erigeron Injection;placebo
50 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

38
Brain, Heart, Testes, Bone, Endothelial, Kidney, Bone Marrow

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 834)
# Title Authors Year
1
Moyamoya-like cerebrovascular disease in a child with a novel mutation in myosin heavy chain 11. ( 29263223 )
2018
2
Comparison of Blood Oxygenation Level-Dependent fMRI and Provocative DSC Perfusion MR Imaging for Monitoring Cerebrovascular Reserve in Intracranial Chronic Cerebrovascular Disease. ( 29371256 )
2018
3
Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. ( 29311290 )
2018
4
Use of cardiovascular polypills for the secondary prevention of cerebrovascular disease. ( 29325730 )
2018
5
On the Reproducibility of Inversion Recovery Intravoxel Incoherent Motion Imaging in Cerebrovascular Disease. ( 29217741 )
2018
6
Association Between Heart Rate and Subclinical Cerebrovascular Disease in the Elderly. ( 29284731 )
2018
7
Haploidentical stem cell transplantation cures autoimmune hepatitis and cerebrovascular disease in a patient with sickle cell disease. ( 29335630 )
2018
8
Lower body functioning and correlates among older American Indians: The Cerebrovascular Disease and Its Consequences in American Indians Study. ( 29304750 )
2018
9
Functional Trajectories, Cognition, and Subclinical Cerebrovascular Disease. ( 29374104 )
2018
10
Lenalidomide-Induced Ischemic Cerebrovascular Disease in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome. ( 29395638 )
2018
11
Brain amyloid burden and cerebrovascular disease are synergistically associated with neurometabolism in cognitively unimpaired older adults. ( 29310864 )
2018
12
Preeclampsia Increases the Incidence of Postpartum Cerebrovascular Disease in Korean Population. ( 29349936 )
2018
13
Cerebrovascular Disease Knowledge Portal: An Open-Access Data Resource to Accelerate Genomic Discoveries in Stroke. ( 29335331 )
2018
14
The effect of demographic features on aortic arch anatomy and its role in the etiology of cerebrovascular disease. ( 29302189 )
2018
15
Depression and Cerebrovascular Disease: What is to be Done? ( 28011139 )
2017
16
Consensus statement on current and emerging methods for the diagnosis and evaluation of cerebrovascular disease. ( 28816594 )
2017
17
Effects of high-intensity pulse irradiation with linear polarized near-infrared rays and stretching on muscle tone in patients with cerebrovascular disease: a randomized controlled trial. ( 28878481 )
2017
18
Effects With and Without Clopidogrel Loading Treatment for Acute Ischemic Cerebrovascular Disease Patients: A Retrospective Cohort Study. ( 28826995 )
2017
19
A panel of clinical and neuropathological features of cerebrovascular disease through the novel neuroimaging methods. ( 29354214 )
2017
20
Increased Levels of Soluble Cluster of Differentiation 40 Ligand, Matrix Metalloproteinase 9, and Matrix Metalloproteinase 2 Are Associated with Carotid Plaque Vulnerability in Patients with Ischemic Cerebrovascular Disease. ( 28642174 )
2017
21
Introducing Focused Updates in Cerebrovascular Disease. ( 28916676 )
2017
22
Social Cognition Deficits: Current Position and Future Directions for Neuropsychological Interventions in Cerebrovascular Disease. ( 28729755 )
2017
23
Response by Bondonno et al to Letter Regarding Article, "Association of Vegetable Nitrate Intake With Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women". ( 28830974 )
2017
24
Cerebrovascular Disease: Consequences of Obesity-Induced Endothelial Dysfunction. ( 28933065 )
2017
25
Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. ( 27980126 )
2017
26
Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. ( 28591212 )
2017
27
CPAP did not reduce cardiovascular events in patients with coronary or cerebrovascular disease and moderate to severe obstructive sleep apnoea. ( 28069600 )
2017
28
Letter by Tsuda Regarding Article, "Association of Vegetable Nitrate Intake With Carotid Atherosclerosis and Ischemic Cerebrovascular Disease in Older Women". ( 28830972 )
2017
29
The burden of mood-disorder/cerebrovascular disease comorbidity: essential neurobiology, psychopharmacology, and physical activity interventions. ( 28681620 )
2017
30
Diabetes, Prediabetes, and Brain Volumes and Subclinical Cerebrovascular Disease on MRI: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). ( 28916531 )
2017
31
Prospective Study on the Incidence of Cerebrovascular Disease After Coronary Angiography. ( 28855432 )
2017
32
The effectiveness and safety of dual antiplatelet therapy in ischemic cerebrovascular disease with intracranial and extracranial arteriostenosis in Chinese patients: A randomized and controlled trail. ( 28072691 )
2017
33
Brain ureido degenerative protein modifications are associated with neuroinflammation and proteinopathy in Alzheimer's disease with cerebrovascular disease. ( 28865468 )
2017
34
Impact of Birth Place and Geographic Location on Risk Disparities in Cerebrovascular Disease: Implications for Future Research. ( 28759684 )
2017
35
Positive Airway Pressure Therapy for Hyperventilatory Central SleepA Apnea: Idiopathic, Heart Failure, Cerebrovascular Disease, and High Altitude. ( 29108611 )
2017
36
Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. ( 27887801 )
2017
37
Effects of aspiration pneumonia on the intensive care requirements and in-hospital mortality of hospitalised patients with acute cerebrovascular disease. ( 28883847 )
2017
38
Association of Blood Pressure Control Level With Left Ventricular Morphology and Function and With Subclinical Cerebrovascular Disease. ( 28757483 )
2017
39
Apoplexy, cerebrovascular disease, and stroke: Historical evolution of terms and definitions. ( 29354227 )
2017
40
A meta-analysis of obstructive sleep apnea in patients with cerebrovascular disease. ( 29248975 )
2017
41
Increased Prevalence of Cerebrovascular Disease in Hospitalized Patients with Ehlers-Danlos Syndrome. ( 28647420 )
2017
42
Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer's disease with and without cerebrovascular disease. ( 28818116 )
2017
43
Subclinical Cerebrovascular Disease Increases the Risk of Incident Stroke and Mortality: The Northern Manhattan Study. ( 28847914 )
2017
44
A Decrease of Brain MicroRNA-122 Level Is an Early Marker of Cerebrovascular Disease in the Stroke-Prone Spontaneously Hypertensive Rat. ( 28751928 )
2017
45
Which antihypertensive drug should be used in patients with cerebrovascular disease to prevent a new stroke? ( 28069253 )
2017
46
Prevention of Alzheimer's disease, cerebrovascular disease and dementia in women: the case for menopause hormone therapy. ( 28074678 )
2017
47
Dipeptidyl Peptidase-4 Inhibitors Use and Relative Risk of Ischemic Cerebrovascular Disease in Type 2 Diabetic Patients in a Case-Control Study. ( 29213240 )
2017
48
The gut microbiota: An emerging risk factor for cardiovascular and cerebrovascular disease. ( 29230812 )
2017
49
Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease. ( 28775374 )
2017
50
Cerebrovascular disease, associated risk factors and antithrombotic therapy in a population screening cohort: Insights from the Belgian Heart Rhythm Week programme. ( 27909151 )
2017

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 APOA1 APOB APOE MTHFR MTR
2
Show member pathways
11.61 APOA1 APOB APOE CBS CRP F2
3
Show member pathways
11.57 APOA1 APOB APOE COL4A1
4
Show member pathways
11.54 ACE AGTR1 REN
5 11.39 ACE AGTR1 REN
6 11.18 APOB PLAT SELP
7 10.76 ACE APOE APP CX3CR1
8 10.69 ACE APP PLAT
9
Show member pathways
10.39